News & Updates
Filter by Specialty:
Suboptimal influenza vaccination persists among insurance holders despite no copayment
The coverage of influenza vaccination for Medicare beneficiaries remains poor, reports a study, noting missed opportunities despite availability of vaccines with no copayment. In addition, there are still disparities in vaccination uptake by race/ethnicity.
Suboptimal influenza vaccination persists among insurance holders despite no copayment
24 Nov 2021Automated text messaging service helps reduce deaths in outpatients with COVID-19
Adults newly diagnosed with COVID-19 in outpatient settings and enrolled in an automated remote monitoring service are less likely to succumb to the disease potentially due to more frequent telemedicine encounters and earlier presentation to the emergency department (ED), a study has shown.
Automated text messaging service helps reduce deaths in outpatients with COVID-19
24 Nov 2021Increased estimated PWV tied to higher hypertension incidence
Estimated pulse wave velocity (ePWV) is significantly associated with mean systolic (SBP) and mean diastolic blood pressure (DBP), with an increase in ePWV resulting in a higher incidence of hypertension, reports a recent study.
Increased estimated PWV tied to higher hypertension incidence
24 Nov 2021Focused ultrasound shows promise in drug-resistant epilepsy
Low-intensity focused ultrasound can be delivered to the target zone in patients with drug-resistant epilepsy without significant adverse events, as shown in a phase I study. Moreover, the treatment produces meaningful changes in stereo-electroencephalography activity.
Focused ultrasound shows promise in drug-resistant epilepsy
24 Nov 2021Hypertension tied to cardiac injury in COVID-19 patients
In patients with the coronavirus disease 2019 (COVID-19), hypertension aggravates the risk of cardiac injury and severe disease phenotype, a recent study has found.
Hypertension tied to cardiac injury in COVID-19 patients
24 Nov 2021Sotrovimab may reduce COVID-19 disease progression
The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.